144 related articles for article (PubMed ID: 20473727)
1. Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.
Hubalek M; Brantner C; Marth C
Wien Med Wochenschr; 2010 Apr; 160(7-8):167-73. PubMed ID: 20473727
[TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.
Figg WD; Cook K; Clarke R
Cancer Biol Ther; 2014; 15(12):1586-7. PubMed ID: 25535893
[TBL] [Abstract][Full Text] [Related]
3. Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal women.
Pritchard K
Breast Cancer Res; 2005; 7(2):70-6. PubMed ID: 15743514
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Shiba E; Yamashita H; Kurebayashi J; Noguchi S; Iwase H; Ohashi Y; Sasai K; Fujimoto T
Breast Cancer; 2016 May; 23(3):499-509. PubMed ID: 25655898
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
Francis PA; Fleming GF; Láng I; Ciruelos EM; Bonnefoi HR; Bellet M; Bernardo A; Climent MA; Martino S; Bermejo B; Burstein HJ; Davidson NE; Geyer CE; Walley BA; Ingle JN; Coleman RE; Müller B; Le Du F; Loibl S; Winer EP; Ruepp B; Loi S; Colleoni M; Coates AS; Gelber RD; Goldhirsch A; Regan MM;
J Clin Oncol; 2023 Mar; 41(7):1370-1375. PubMed ID: 36493334
[No Abstract] [Full Text] [Related]
6. Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectives.
Love RR
Oncology (Williston Park); 2010 Apr; 24(4):322-7. PubMed ID: 20464842
[TBL] [Abstract][Full Text] [Related]
7. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
Regan MM; Walley BA; Francis PA; Fleming GF; Láng I; Gómez HL; Colleoni M; Tondini C; Pinotti G; Salim M; Spazzapan S; Parmar V; Ruhstaller T; Abdi EA; Gelber RD; Coates AS; Goldhirsch A; Pagani O
Ann Oncol; 2017 Sep; 28(9):2225-2232. PubMed ID: 28911092
[TBL] [Abstract][Full Text] [Related]
8. Latent class joint model of ovarian function suppression and DFS for premenopausal breast cancer patients.
Zhang JJ; Wang M
Stat Med; 2010 Sep; 29(22):2310-24. PubMed ID: 20552577
[TBL] [Abstract][Full Text] [Related]
9. Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial.
Baek SY; Noh WC; Ahn SH; Kim HA; Ryu JM; Kim SI; Lee EG; Im SA; Jung Y; Park MH; Park KH; Kang SH; Jeong J; Park E; Kim SY; Lee MH; Kim LS; Lim W; Kim S; Kim HJ
J Clin Oncol; 2023 Nov; 41(31):4864-4871. PubMed ID: 37607321
[TBL] [Abstract][Full Text] [Related]
10. Ovarian Suppression: Early Menopause and Late Effects.
Molinelli C; Jacobs F; Nader-Marta G; Borea R; Scavone G; Ottonello S; Fregatti P; Villarreal-Garza C; Bajpai J; Kim HJ; Puglisi S; de Azambuja E; Lambertini M
Curr Treat Options Oncol; 2024 Apr; 25(4):523-542. PubMed ID: 38478329
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Adjuvant Endocrine Therapy With Ovarian Suppression in Premenopausal Patients With Hormone Receptor-Positive Early Breast Cancer in China.
Zhong X; Chen P; He P; Wu Y; Suo J; Zhu K; Yan X; Tian T; Yang Q; Luo T
Clin Breast Cancer; 2024 Feb; 24(2):e41-e50. PubMed ID: 37865566
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico.
Villarreal-Garza C; Mesa-Chavez F; Ferrigno AS; De la Garza-Ramos C; Fonseca A; Villanueva-Tamez K; Campos-Salgado JY; Cruz-Ramos M; Rodriguez-Gomez DO; Ruiz-Cruz S; Cabrera-Galeana P
Breast; 2021 Oct; 59():8-15. PubMed ID: 34116366
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer.
Venturelli M; Guaitoli G; Omarini C; Moscetti L
Breast Cancer (Dove Med Press); 2018; 10():39-49. PubMed ID: 29551913
[TBL] [Abstract][Full Text] [Related]
14. Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study.
Heredia A; Walbaum B; Vidal M; Itriago L; Camus M; Dominguez F; Manzor M; Martínez R; Murature G; Muñiz S; Navarro M; Guerra C; Merino T; Medina L; Ibañez C; Ramirez K; Acevedo F; Sánchez C
Breast Cancer Res Treat; 2024 Jan; 203(1):173-179. PubMed ID: 37733187
[TBL] [Abstract][Full Text] [Related]
15. Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research.
Conforti F; Pala L; De Pas T; Zattarin E; Catania C; Cocorocchio E; Rossi G; Laszlo D; Colleoni M; Zambelli A; Hortobagyi GN; Cortes J; Piccart MJ; Dowsett M; Gelber RD; Viale G
Clin Cancer Res; 2024 Mar; 30(6):1093-1103. PubMed ID: 37906083
[TBL] [Abstract][Full Text] [Related]
16. Benefits and adverse effects of endocrine therapy.
Colleoni M; Giobbie-Hurder A
Ann Oncol; 2010 Oct; 21 Suppl 7(Suppl 7):vii107-11. PubMed ID: 20943602
[TBL] [Abstract][Full Text] [Related]
17. Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer.
Sa-Nguanraksa D; Krisorakun T; Pongthong W; O-Charoenrat P
Mol Clin Oncol; 2019 Nov; 11(5):517-522. PubMed ID: 31620283
[TBL] [Abstract][Full Text] [Related]
18. Omission of surgery, primary endocrine therapy adherence, and effect of comorbidity in older women with estrogen receptor positive breast cancer.
Carleton N; Abidi H; Puthanmadhom-Narayanan S; Marroquin OC; Oesterreich S; Diego EJ; Brufsky AM; Lee AV; McAuliffe PF
J Geriatr Oncol; 2024 Apr; 15(3):101679. PubMed ID: 38135542
[No Abstract] [Full Text] [Related]
19. Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.
Balazard F; Bertaut A; Bordet É; Mulard S; Blanc J; Briot N; Paux G; Dhaini Merimeche A; Rigal O; Coutant C; Fournier M; Jouannaud C; Soulie P; Lerebours F; Cottu PH; Tredan O; Vanlemmens L; Levy C; Mouret-Reynier MA; Campone M; Brady KJS; Sasane M; Rice M; Coulouvrat C; Martin AL; Jacquet A; Vaz-Luis I; Herold C; Pistilli B
J Natl Cancer Inst; 2023 Sep; 115(9):1099-1108. PubMed ID: 37434306
[TBL] [Abstract][Full Text] [Related]
20. The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer.
Rossi L; Pagani O
Breast Care (Basel); 2015 Oct; 10(5):312-5. PubMed ID: 26688677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
